Development of a Practical Large-Scale Synthesis of Denagliptin Tosylate
作者:Daniel E. Patterson、Jeremiah D. Powers、Michael LeBlanc、Tyler Sharkey、Emily Boehler、Erwin Irdam、Martin H. Osterhout
DOI:10.1021/op900178d
日期:2009.9.18
A large-scalesynthesis of denagliptin tosylate has been developed. The efficiency of the synthesis has been improved from the initially scaled route by changing the order of steps (performing a dehydration at a late stage). The key step of the synthesis is a single-step peptide coupling/dehydration, mediated by n-propanephosphonic acid cyclic anhydride. The challenges of developing this synthesis into
[EN] ANHYDROUS CRYSTALLINE FORMS OF (2S, 4S)-1-{(2R)-2-AMINO-3-'4-METHOXYBENZYL)SULFONYL!-3-METHYLBUTANOYL}-4-FLUOROPYRROLINDINE-2-CARBONITRILE<br/>[FR] FORMES CRISTALLINES ANHYDRES DE (2S, 4S)-1-{(2R)-2-AMINO-3-'4-METHOXYBENZYL)SULFONYL!-3-METHYLBUTANOYL}-4-FLUOROPYRROLINDINE-2-CARBONITRILE
申请人:SMITHKLINE BEECHAM CORP
公开号:WO2004092128A1
公开(公告)日:2004-10-28
The present invention includes anhydrous crystalline forms of (2S,4S)-1-(2R)-2-amino-3-[(4-methoxybenzyl)sulfonyl]-3-methylbutanoyl}-4-fluoropyrrolidine-2-carbonitrile. Formula (I).
NOVEL PROCESSES FOR THE PREPARATION OF DPP IV INHIBITORS
申请人:Thomas Abraham
公开号:US20080076818A1
公开(公告)日:2008-03-27
The present invention relates to novel processes for preparing DPP-IV inhibitors having the structure of formula I,
and pharmaceutically acceptable salt thereof, which are useful for treatment of Type 2 diabetes.
Processes for the preparation of DPP IV inhibitors
申请人:Glenmark Pharmaceuticals, S.A.
公开号:US07893103B2
公开(公告)日:2011-02-22
The present invention relates to novel processes for preparing DPP-IV inhibitors having the structure of formula I,
and pharmaceutically acceptable salt thereof, which are useful for treatment of Type 2 diabetes.